NASDAQ:RDUS

Radius Health Competitors

$19.61
+0.71 (+3.76 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$19.06
Now: $19.61
$19.86
50-Day Range
$18.60
MA: $21.03
$25.77
52-Week Range
$10.15
Now: $19.61
$26.16
Volume17,256 shs
Average Volume484,729 shs
Market Capitalization$919.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Radius Health (NASDAQ:RDUS) Vs. LEGN, NKTR, APLS, PTCT, ACAD, and CCXI

Should you be buying RDUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Radius Health, including Legend Biotech (LEGN), Nektar Therapeutics (NKTR), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), and ChemoCentryx (CCXI).

Legend Biotech (NASDAQ:LEGN) and Radius Health (NASDAQ:RDUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Legend Biotech and Radius Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Legend Biotech00303.00
Radius Health06302.33

Legend Biotech currently has a consensus price target of $50.6667, indicating a potential upside of 89.34%. Radius Health has a consensus price target of $24.60, indicating a potential upside of 25.45%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Legend Biotech is more favorable than Radius Health.

Profitability

This table compares Legend Biotech and Radius Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Legend Biotech-543.73%-205.60%-43.03%
Radius Health-48.61%N/A-56.85%

Insider & Institutional Ownership

18.9% of Legend Biotech shares are owned by institutional investors. 2.9% of Radius Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Legend Biotech and Radius Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$64.39 million54.86$-132,970,000.00N/AN/A
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79

Legend Biotech has higher earnings, but lower revenue than Radius Health.

Summary

Legend Biotech beats Radius Health on 6 of the 10 factors compared between the two stocks.

Radius Health (NASDAQ:RDUS) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Profitability

This table compares Radius Health and Nektar Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Radius Health-48.61%N/A-56.85%
Nektar Therapeutics-269.05%-30.74%-22.63%

Volatility & Risk

Radius Health has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Radius Health and Nektar Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Radius Health06302.33
Nektar Therapeutics16102.00

Radius Health currently has a consensus price target of $24.60, suggesting a potential upside of 25.45%. Nektar Therapeutics has a consensus price target of $25.2857, suggesting a potential upside of 32.18%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Radius Health.

Valuation and Earnings

This table compares Radius Health and Nektar Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79
Nektar Therapeutics$114.62 million30.42$-440,670,000.00($2.52)-7.59

Radius Health has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. 2.9% of Radius Health shares are held by insiders. Comparatively, 3.0% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Nektar Therapeutics beats Radius Health on 8 of the 14 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Radius Health (NASDAQ:RDUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Apellis Pharmaceuticals and Radius Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Radius Health-48.61%N/A-56.85%

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Apellis Pharmaceuticals and Radius Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Radius Health06302.33

Apellis Pharmaceuticals presently has a consensus target price of $124.6154, suggesting a potential upside of 180.29%. Radius Health has a consensus target price of $24.60, suggesting a potential upside of 25.45%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Apellis Pharmaceuticals is more favorable than Radius Health.

Valuation and Earnings

This table compares Apellis Pharmaceuticals and Radius Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.58
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79

Radius Health has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Radius Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Apellis Pharmaceuticals beats Radius Health on 9 of the 14 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Radius Health (NASDAQ:RDUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Volatility & Risk

PTC Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Profitability

This table compares PTC Therapeutics and Radius Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-123.19%-76.10%-24.60%
Radius Health-48.61%N/A-56.85%

Valuation and Earnings

This table compares PTC Therapeutics and Radius Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million10.97$-251,580,000.00($3.45)-13.88
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79

Radius Health has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for PTC Therapeutics and Radius Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics05702.58
Radius Health06302.33

PTC Therapeutics presently has a consensus target price of $64.90, suggesting a potential upside of 35.52%. Radius Health has a consensus target price of $24.60, suggesting a potential upside of 25.45%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe PTC Therapeutics is more favorable than Radius Health.

Summary

PTC Therapeutics beats Radius Health on 8 of the 12 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Radius Health (NASDAQ:RDUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares ACADIA Pharmaceuticals and Radius Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million10.04$-235,260,000.00($1.60)-13.29
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79

Radius Health has lower revenue, but higher earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ACADIA Pharmaceuticals and Radius Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
Radius Health-48.61%N/A-56.85%

Volatility & Risk

ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Radius Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for ACADIA Pharmaceuticals and Radius Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals012702.37
Radius Health06302.33

ACADIA Pharmaceuticals currently has a consensus price target of $32.7647, suggesting a potential upside of 54.04%. Radius Health has a consensus price target of $24.60, suggesting a potential upside of 25.45%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ACADIA Pharmaceuticals is more favorable than Radius Health.

Summary

ACADIA Pharmaceuticals beats Radius Health on 10 of the 14 factors compared between the two stocks.

Radius Health (NASDAQ:RDUS) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Radius Health and ChemoCentryx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Radius Health$173.32 million5.31$-132,990,000.00($2.89)-6.79
ChemoCentryx$36.13 million91.40$-55,490,000.00($0.98)-48.32

ChemoCentryx has lower revenue, but higher earnings than Radius Health. ChemoCentryx is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Radius Health has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Profitability

This table compares Radius Health and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Radius Health-48.61%N/A-56.85%
ChemoCentryx-58.10%-17.23%-11.07%

Institutional and Insider Ownership

80.7% of ChemoCentryx shares are owned by institutional investors. 2.9% of Radius Health shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Radius Health and ChemoCentryx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Radius Health06302.33
ChemoCentryx01713.00

Radius Health currently has a consensus price target of $24.60, suggesting a potential upside of 25.45%. ChemoCentryx has a consensus price target of $80.7778, suggesting a potential upside of 70.60%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts plainly believe ChemoCentryx is more favorable than Radius Health.

Summary

ChemoCentryx beats Radius Health on 11 of the 15 factors compared between the two stocks.


Radius Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LEGN
Legend Biotech
1.2$26.76+1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.13+2.3%$3.41 billion$114.62 million-7.71Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.46+5.0%$3.40 billionN/A-5.99News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.89+1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.27+3.1%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.35+0.4%$3.29 billion$36.13 million-70.67Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.01+4.0%$3.27 billion$136.47 million-12.70
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.72+3.6%$3.13 billion$26.52 million-7.90
Alkermes logo
ALKS
Alkermes
1.2$19.21+1.8%$3.00 billion$1.17 billion-41.76
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$115.59+3.9%$3.00 billionN/A-57.51Insider Selling
Gap Down
Arvinas logo
ARVN
Arvinas
1.5$62.76+2.3%$3.00 billion$42.98 million-24.52News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.48+1.8%$2.99 billion$421.03 million24.46Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.68+1.4%$2.94 billion$80.43 million108.01Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.77 billion$644.77 million-10.39
OPKO Health logo
OPK
OPKO Health
1.9$4.20+1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.70 billion$260.98 million-365.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.00+3.1%$2.61 billion$306.49 million25.84
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.33+2.9%$2.60 billionN/A-23.81
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.51 billion$60,000.00-10.02
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$46.03+5.6%$2.50 billion$25 million-9.21Insider Selling
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.36+2.9%$2.50 billion$2.11 million-8.95Analyst Report
News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.46 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.83+2.5%$2.44 billion$120.28 million-152.35Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$51.65+1.2%$2.38 billion$33.94 million-89.05
Xencor logo
XNCR
Xencor
1.0$43.17+6.9%$2.33 billion$156.70 million-30.84News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21+2.3%$2.30 billion$15 million-17.39Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.45+4.0%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81+0.5%$2.20 billion$963.01 million13.61News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.77+3.4%$2.05 billion$23.90 million-17.25Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.10+0.4%$2.00 billion$429.76 million-101.98News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13+1.2%$1.98 billion$410,000.00-6.12Analyst Report
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.53+3.4%$1.93 billionN/A-19.90
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.64+1.7%$1.92 billion$34.51 million-17.64
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93+2.6%$1.91 billionN/A-27.20Increase in Short Interest
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01+2.9%$1.87 billionN/A0.00Analyst Report
Gap Down
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80+5.3%$1.87 billion$103.54 million-19.40Insider Selling
MORF
Morphic
1.3$55.69+3.5%$1.87 billion$16.98 million-35.70Insider Selling
Decrease in Short Interest
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.67+4.2%$1.85 billionN/A-10.90
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20+5.8%$1.82 billionN/A-17.91Gap Down
FibroGen logo
FGEN
FibroGen
1.8$19.24+2.5%$1.81 billion$256.58 million-7.37Analyst Report
News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$31.28+5.5%$1.77 billion$64.19 million-9.99Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.98+0.1%$1.77 billion$14.87 million-14.17Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.82+1.0%$1.73 billion$1.63 billion14.20Analyst Report
Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.23+1.3%$1.71 billion$26.87 million-12.69Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.63+3.0%$1.66 billion$428.41 million15.41News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.91+1.9%$1.66 billion$392.76 million13.24Analyst Upgrade
Analyst Revision
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.59+1.6%$1.63 billion$320,000.00-8.56Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$29.06+2.1%$1.62 billionN/A0.00Analyst Revision
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.